References
- Yao JC, Hassan M, Phan A, et al. One-hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:2063‐3072
- Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458‐511
- Yim KL. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocr 2011; 40:181--186
- Buchanan KD, Johnston CF, O’Hare MM, et al. Neuroendocrine tumors. A European view. Am J Med 1986;81:14‐22
- Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol 2011;29:934‐43
- Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 2012;8:54--64
- Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford: OUP, 2005
- National Institute for Health & Clinical Excellence (NICE). Guide to the methods of technology appraisal, NICE: London, UK June 2008 http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf. Accessed January 15, 2010
- Lloyd A, Wild D, Gallop K, et al. Reimbursement agency requirements for health related quality-of-life data: a case study. Expert Rev Pharmacoecon Outcomes Res 2009;9:527‐37
- Brooks R. EuroQol: the current state of play. Health Policy 1996;7:53‐72
- Torrance GW, Thomas WH, Sackett DL. A utility maximization model of evaluation of health care programs. Health Serv Res 1972;7:118‐33
- Davies AH, Larsson G, Ardill J, et al. Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer 2006;42:477‐84
- Fröjd C, Larsson G, Lampic C, et al. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective and comparative study. Health Qual Life Outcomes 2007;5:18
- Haugland T, Vatn MH, Veenstra M, et al. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual Life Res 2009;18:719‐26
- Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 2004;22:2724‐9
- Office of National Statistics. Population of the United Kingdom: by ethnic group. National Statistics website, 2001. http://www.statistics.gov.uk/CCI/nugget.asp?ID¼273. Accessed January 15, 2010
- Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1‐30
- Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736‐41
- Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009;45:1397‐406
- Esnaola NF, Lazarides SN, Mentzer SJ, et al. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer. J Clin Oncol 2002;20:263‐73
- Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 2009;25:401‐11
- Scottish Medical Consortium. Advice for the use of Sutent in the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. 2011 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/698_11_sunitinib_Sutent_with_PAS/sunitinib_Sutent_with_PAS. Accessed September 30, 2011